Added to YB: 2024-04-12
Pitch date: 2024-04-09
VKTX [bullish]
Viking Therapeutics, Inc.
-47.4%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders.
Market Cap
$4.4B
Pitch Price
$70.50
Price Target
N/A
Dividend
N/A
EV/EBITDA
-13.51
P/E
-18.45
EV/Sales
N/A
Sector
Biotechnology
Category
growth
Show full summary:
ClearBridge Small Cap Growth Strategy New Position: Viking Therapeutics, Inc.
VKTX: Promising metabolic & endocrine drug pipeline. Ph2 GLP-1/GIP injectable shows potential vs rivals. Oral obesity, NASH programs add upside. Obesity market growth, scarcity value & cash to fund near-term development make it an attractive small cap opportunity.
Read full article (1 min)